Advertisement
U.S. markets close in 2 hours 4 minutes
  • S&P 500

    5,252.23
    +3.74 (+0.07%)
     
  • Dow 30

    39,779.43
    +19.35 (+0.05%)
     
  • Nasdaq

    16,379.60
    -19.92 (-0.12%)
     
  • Russell 2000

    2,124.92
    +10.57 (+0.50%)
     
  • Crude Oil

    83.01
    +1.66 (+2.04%)
     
  • Gold

    2,241.60
    +28.90 (+1.31%)
     
  • Silver

    24.97
    +0.21 (+0.86%)
     
  • EUR/USD

    1.0799
    -0.0030 (-0.28%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.09%)
     
  • USD/JPY

    151.3710
    +0.1250 (+0.08%)
     
  • Bitcoin USD

    70,823.62
    +1,911.24 (+2.77%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

A Biotech ETF for Up-and-Coming Drug Developers

I do the “ETF of the Week” for MarketWatch every Thursday on Chuck Jaffe’s MoneyLife Show where I highlight big movers and disappointments within the exchange traded fund market.

This Thursday, I took a look at the SPDR S&P Biotech ETF (XBI) . Instead of betting on a few small up-and-coming biotechnology firms, this equal-weight biotech ETF helps provide a diversified approach to the industry.

Click here to listen to the podcast.

To access previous podcasts, take a look at our podcasts category.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Advertisement